Spago Nanomedical AB (publ)
SPAGO
Rank in Stocks
#31122
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to... Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.
Share Price
$0.00448359
Last synced: 2026-11-13
Market Cap
$3.58M
Change (1 day)
-1.11%
Change (1 year)
-63.53%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Spago Nanomedical AB (publ) (SPAGO)
Category
Healthcare
Operating Margin for Spago Nanomedical AB (publ) (SPAGO)
Operating Margin as of November 2026 TTM: -115,350.00%
According to Spago Nanomedical AB (publ)'s latest financial reports, its current operating margin (TTM) is -115,350.00%. At the end of 2025 the company had an operating margin of -7,062.70%.
Operating Margin history for Spago Nanomedical AB (publ) from 2011 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -115,350.00% | 1,533.23% |
| 2025 | -7,062.70% | 300.35% |
| 2024 | -1,764.15% | -55.07% |
| 2023 | -3,926.27% | 4.86% |
| 2022 | -3,744.31% | -36.95% |
| 2021 | -5,938.18% | 7.10% |
| 2020 | -5,544.44% | -91.74% |
| 2019 | -67,140.00% | 179,322.77% |
| 2018 | -37.42% | -99.81% |
| 2017 | -19,331.91% | 53.45% |
| 2016 | -12,598.28% | 7,561.79% |
| 2015 | -164.43% | -98.49% |
| 2014 | -10,879.63% | 391.78% |
| 2013 | -2,212.28% | 37.88% |
| 2012 | -1,604.50% | 2,101.56% |
| 2011 | -72.88% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -100.00% |
US
|
|
| 33.87% | -100.00% |
US
|
|
| -116.04% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Spago Nanomedical AB (publ)'s operating margin
What is Spago Nanomedical AB (publ)'s operating margin?
Spago Nanomedical AB (publ)'s operating margin is -115,350.00%, as of Nov 2026.
What was Spago Nanomedical AB (publ)'s operating margin in 2025?
In 2025, Spago Nanomedical AB (publ)'s operating margin was -7,062.70%, compared with -1,764.15% in 2024.
How has Spago Nanomedical AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Spago Nanomedical AB (publ)'s operating margin was highest in 2024 (-1,764.15%) and lowest in 2025 (-7,062.70%).
How does Spago Nanomedical AB (publ)'s operating margin compare with similar companies?
Spago Nanomedical AB (publ)'s operating margin (-115,350.00%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.